Peking University First Hospital
Beijing, China
NCT Number: NCT07020949
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Beijing, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants received THDBH120 by subcutaneous injection.
Participants received placebo by subcutaneous injection.
Time frame: 78 days
Time frame: Day 1 Pre-dose through Day 43
Time frame: Day 1 Pre-dose through Day 43
Time frame: 43 days
Time frame: 78 days
Tonghua Dongbao Pharmaceutical Co.,Ltd
Industry
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05330247
Body Weight, Diabetes Mellitus
Copenhagen, Copenhagen NV, Denmark
View Trial DetailsNCT07677865
Alzheimer Disease, Body Weight
Chengdu, Sichuan, China
View Trial DetailsNCT06638099
Diabetes, Diabetes Mellitus
El Centro, California, United States
View Trial DetailsNCT07647406
Diabetes Mellitus, Diabetes Mellitus Type 2
Pančevo, Vojvodina, Serbia
View Trial Details